Hospital-Acquired Infection Control Market Latest Research On Industry Growth, Trends, Top Players, & Key Regions By 2027

SHARE THIS ARTICLE

New York, United States: The Report on Hospital-Acquired Infection Control Market by Decisive Markets Insights was released in the middle of Covid -19 after a thorough analysis of the top players and primary interviews with key industry figures. A market study from Hospital-Acquired Infection Control Market examines the market size, segmentation, future trends, growth rate, drivers and challenges, as well as the sales channels and distributors

The global Hospital-Acquired Infection Control market gathered revenue around USD 19,959 Million in 2020 and market is set to grow USD 25,010 Million by the end of 2027 and is estimated to expand at a modest CAGR of 6.7% during the prediction period 2021 to 2027.

Overview of Hospital-Acquired Infection Control Market Study

Hospital-Acquired Infection Control market study conducted by Nova One Advisor is intended at helping stakeholders get a comprehensive overview of potential challenges and undiscovered opportunities. The report offers exclusive insights to help companies and their customers to make informed decision to sustain growth through the assessment period.

Get your Customized Research Report@ https://www.novaoneadvisor.com/report/customization/5570

Growth Factors:

The growth of the hospital acquired infection control market can largely be attributed to factors such as the high incidence of hospital-acquired infections, the increasing number of surgical procedures, the growing geriatric population and the increasing incidence of chronic diseases, technological advancements in sterilization equipment, and the growing awareness of environmental & personal hygiene due to COVID-19. The increasing use of E-beam sterilization, reintroduction of ethylene oxide sterilization, and the growing healthcare industry and outsourcing of operation to emerging countries are expected to offer high-growth opportunities for market players during the forecast period.

Currently, with the surge in COVID-19 cases, there is an increasing focus on personal hygiene along with the increasing production of medical nonwovens and single-use products such as face masks and gloves. This is further expected to drive the growth of the hospital acquired infection control market in the coming years. On the other hand, concerns regarding the safety of reprocessed instruments are expected to limit market growth to some extent in the coming years. This, along with factors such as the high cost of endoscope reprocessing and limited reimbursement in developing countries and end-user noncompliance with sterilization standards, is expected to restrain the growth of hospital acquired infection control market.

HOSPITAL ACQUIRED INFECTION CONTROL MARKET DYNAMICS
Driver: Increasing number of surgical procedures
Over the years, there has been a significant rise in the number of surgical procedures performed worldwide. According to the WHO (2019), approximately 235 million major surgical procedures are performed worldwide every year. This is attributed to the growing prevalence of obesity and other lifestyle diseases, the rising geriatric population, and the increasing incidence of spinal injuries and sports-related injuries. The growing number of surgical procedures performed has resulted in the increasing demand for different surgical equipment and medical devices. This is expected to drive the demand for hospital acquired infection services due to the proven benefits of sterilized products and growing awareness about their effectiveness in healthcare settings.

Restraint: Concerns regarding the safety of reprocessed instruments
Healthcare providers reprocess reusable medical devices to save money and reduce waste. Examples of reusable medical devices include surgical forceps, endoscopes, and stethoscopes. However, there are concerns about the safety and performance of reprocessed devices. Inadequate cleaning and sterilization of instruments can result in the retention of blood, tissue, and other biological debris in reusable devices, which increases the risk of surgical-site infections (SSIs) in patients. The debris can allow microbes to survive the subsequent disinfection or sterilization process, which could then lead to HAIs. Inadequate reprocessing can also result in other adverse patient outcomes, such as tissue irritation from residual reprocessing materials such as chemical disinfectants. These factors are limiting the acceptance of reprocessing among hospital administrators and physicians.

Opportunity: Reintroduction of ethylene oxide sterilization
Ethylene oxide is one of the most effective gaseous sterilizing agents for instruments susceptible to high temperatures, such as plastic instruments and instruments with electrical components. However, the CDC has stated that chronic exposure to ethylene oxide in workplaces can cause cancer. Also, ethylene oxide sterilization can irritate the skin and mucous membranes, resulting in CNS abnormalities in humans. Similarly, acute exposure to EtO gas may result in respiratory irritation, lung injury, headache, nausea, vomiting, diarrhea, shortness of breath, and cyanosis. EtO also degrades in the atmosphere by reacting with photochemically produced hydroxyl radicals. Authorities in several countries have defined regulatory frameworks to govern EtO usage in specific sterilization applications. In December 2016, the US Environmental Protection Agency (EPA), under the Integrated Risk Information System (IRIS) Assessment Program, declared ethylene oxide a probable human carcinogen. The European Union has already banned the use of ethylene oxide for any food fumigation due to safety and environmental concerns. The use of EtO for sterilizing ground spices is forbidden in the US.

However, with the growing number of COVID-19 cases worldwide, the adoption of EtO has increased to sterilize protective gear and single-use instruments before their initial use. This sterilization technology plays a vital role in enabling the sterilization of critical medical products and devices before reaching patients. According to the FDA, more than 20 billion devices sold in the US every year are sterilized with EtO, accounting for approximately 50% of the devices that require sterilization.

Challenge: Complications associated with hospital acquired infection control procedures
There are certain concerns related to the cleaning, disinfection, and sterilization of advanced medical devices. Inadequate sterilization and disinfection of these devices might expose patients to the risk of acquiring HAIs. Moreover, with the introduction of technologically advanced instruments such as endoscopes and analyzers in the market, there is a growing need for advanced sterilizers compatible with the automated endoscope reprocessors used for cleaning and disinfecting flexible endoscopes after each procedure. Inappropriate disinfection of these complex and delicate instruments can increase the risk of infection among patients. An AER that is difficult to use or one that breaks down frequently can significantly increase the risk of improper or ineffective endoscope cleaning and create costly delays. Currently, reprocessing of these instruments after every use is a major challenge faced by healthcare providers in complying with infection control standards.

The Association for the Advancement of Medical Instrumentation has several working groups focusing on developing standards in several areas aimed to address the challenges involved in reprocessing medical devices. These working groups are focusing on instructions for reusable device reprocessing, steam sterilization hospital practices, reusable surgical textiles processing, endoscope reprocessing, human factors for device reprocessing, quality systems for device reprocessing, and cleaning of reusable medical devices. Reprocessing medical devices is a difficult and complex job. Currently, hospitals are demanding sterile processing staff to be certified as it is a skill-intensive process.

The ethylene oxide (EtO) sterilization segment is expected to account for the largest share of the hospital acquired infection control market in 2020
Based on method, the market has been classified into ethylene oxide (EtO) sterilization, gamma sterilization, electron beam (e-beam) radiation sterilization, steam sterilization, x-ray irradiation, and other sterilization methods. The ethylene oxide (EtO) sterilization segment accounted for the largest share of the hospital acquired infection control market in 2020. This segment’s large share can be attributed to its extensive usage in various applications, including medical device sterilization, food testing, pharmaceutical sterilization, and sterilization and disinfection in the life sciences industry.

In 2020, the protective barrier segment accounted for the largest share of the global hospital acquired infection control market
Based on the products and services used in the control of HAIs, the hospital acquired infection control market is segmented into sterilization, disinfectors, endoscope reprocessing products, disinfectants, protective barriers, and other infection control products. In 2020, the protective barrier segment accounted for the largest share of the global hospital acquired infection control market. Once the pandemic situation returns to normalcy, the purchase of protective barriers will witness a downward trend. This is expected to result in a negative growth rate of the protective barriers segment.

The ambulatory surgical and diagnostic centers segment is expected to witness the highest CAGR during the forecast time
Based on end user, the hospital acquired infection control market has been segmented into hospitals & intensive care units (ICUs), ambulatory surgical and diagnostic centers, nursing homes and maternity centers, and other end users (dental clinics, trauma centers, and clinical laboratories). The ambulatory surgical and diagnostic centers segment is expected to witness the highest CAGR during the forecast time. The highest CAGR of this market is majorly attributed to the rising prevalence of HAIs, increasing adoption of single-use medical devices, growing medical devices industry, and rising number of surgical procedures worldwide. Also, increasing demand for minimally invasive surgeries, and growth in the development of outpatient services fuel the growth of the ambulatory surgical centers. In addition, the number of outpatients has increased significantly as a result of increased public health awareness and initiatives by the government to provide ambulatory healthcare services.

North America is expected to account for the largest share of the hospital acquired infection control market in 2020
In 2020, North America accounted for the largest share of the global hospital acquired infection market. Market growth in this region is characterized by the growing demand for and adoption of sterilization and disinfection products along with services as a result of the rising focus on healthy lifestyles and disease prevention among consumers. The surge in the geriatric population in the coming years and the subsequent increase in the prevalence of chronic diseases, the need for hospital acquired infection control to minimize the prevalence of HAIs, and implementation of favorable government initiatives and stringent regulations on sterilization and disinfection are also propelling the hospital acquired infection market in the region.

Buy Complete Assessment of Hospital-Acquired Infection Control market Now@ https://www.novaoneadvisor.com/report/checkout/5570

COVID-19 Impact on Hospital-Acquired Infection Control Sales

Businesses today are operating in a dynamic environment. Earlier focus primarily concentrated on keeping pace with changing consumer preferences. COVID-19 outbreak was unprecedented and exposed vulnerabilities of various industries. Pandemic-induces obstacles also were registered in the Hospital-Acquired Infection Control market.

Sales plummeted as COVID-19 gradually tightened its noose worldwide. Supply-chain disruptions caused massive losses, while demand took nose-dive as consumers remained indoors with affected countries implementing either partial or complete lockdown.

Gradual recovery however is on the cards with the roll out of vaccinations. Nonetheless, consecutive waves of the virus compelled businesses to stay prepared for the worst. As government and healthcare organizations successfully implement steps to contain the spread of COVID-19, industries have begun operations, albeit at a slow and more cautious pace.

Against this backdrop, Nova one advisor’s study predicts gradual recovery for the Hospital-Acquired Infection Control market 2021 onwards. This trend will however continue through the course of the report’s assessment period

Key Players:

This report provides detailed company profiles of the key market players. This research report also highlights the competitive landscape of the Hospital-Acquired Infection Control market and ranks noticeable companies as per their occurrence in diverse regions across globe and crucial developments initiated by them in the market space. This research study also tracks and evaluates competitive developments, such as collaborations, partnerships, and agreements, mergers and acquisitions; novel product introductions and developments, promotion strategies and Research and Development (R&D) activities in the marketplace. The competitive profiling of these players includes business and financial overview, gross margin, production, sales, and recent developments which can aid in assessing competition in the market.

Some of the prominent players in the Hospital-Acquired Infection Control market include:

3M Company, Belimed AG, Ecolab Inc, Fortive (Advanced Sterilization Products), Getinge AB, Matachana Group, Miele Group, MMM Group, Sotera Health LLC, and Steris Plc. (Cantel Medical Corporation).

Unravelling the Critical Segments

This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects including product type, application/end-user, and region. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for period 2017 to 2027 and covers subsequent region in its scope:

Market Segments

By Product & Service

  • Sterilization
    • Sterilization Product
      • Heat Sterilization Equipment
      • Low Temperature Sterilization Equipment
      • Radiation Sterilization Equipment
      • Other Sterilization Equipment
    • Contract Sterilization Services
    • Sterilization Consumables & Accessories
  • Cleaning & Disinfection Products
    • Disinfectants
    • Disinfectors Equipment
    • Others
  • Protective Barriers
  • Endoscope Reprocessing Products

By Infection Type

  • Hospital-acquired Pneumonia
  • Bloodstream Infections
  • Surgical Site Infections
  • Gastrointestinal Infections
  • Urinary Tract Infections (UTI)
  • Others

By End User

  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Others

Why Buy this Report?

The purpose of Nova one advisor’s Hospital-Acquired Infection Control market study is to provide stakeholders with a detailed picture of potential barriers and untapped opportunities. The report contains exclusive information to assist businesses in making informed decisions about how to maintain growth throughout the assessment period.

Download This Full Research Report, Click Here@ https://www.novaoneadvisor.com/report/checkout/5570

About Us

Nova One Advisor is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Nova One Advisor has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@novaoneadvisor.com

Web: https://www.novaoneadvisor.com/

James Root

James Root have over 6+ years of experience working in business development, and customer retention. I’ve gained my experience through serving higher education, healthcare, automotive, aerospace, manufacturing, local government and hospitality businesses with technical solutions.

View all posts by James Root →

Leave a Reply

Your email address will not be published. Required fields are marked *